Multi-functional particles and methods of using the same
AssigneeClemson University Research Foundation
InventorJeoung Soo Lee
Life of this patent
Estimating the term…
Abstract
Provided herein are multi-functional particles. The particles may include poly(lactide-co-glycolide)-g-polyethylenimine (PLGA-g-PEI (PgP)), at least one targeting moiety, at least one therapeutic agent, and/or at least one nucleic acid. Also provided herein are methods of using the multi-functional particles.
Claims20
A method of delivering two or more therapeutic agents to a target, the method comprising:
- administering a micelle to the target, wherein the micelle comprises poly(lactide-co-glycolide)-graft-polyethylenimine (PLGA-g-PEI (PgP)) and the two or more therapeutic agents,
- wherein the two or more therapeutic agents comprise an antiproliferative drug and an antithrombotic drug;
- wherein the micelle has an interior hydrophobic core and a shell having a hydrophilic exterior surface;
- wherein PLGA-g-PEI forms the micelle, and at least a portion of PLGA of PLGA-g-PEI forms at least a portion of the interior hydrophobic core and at least a portion of PEI of PLGA-g-PEI forms at least a portion of the hydrophilic exterior surface of the shell;
- wherein the micelle comprises 2-7 molecules of PLGA grafted to branched chain PEI with the PLGA having a molecular weight of 20 kDaltons to 100 kDaltons;
- and
- wherein the micelle has a diameter in a range of about 100 nm to about 300 nm, thereby delivering the two or more therapeutic agents to the target.
A method of increasing the therapeutic efficacy of at least one therapeutic agent in a subject, the method comprising:
- administering a micelle to the subject, wherein the micelle comprises poly(lactide-co-glycolide)-graft-polyethylenimine (PLGA-g-PEI (PgP)) and at least two therapeutic agents,
- wherein the micelle has an interior hydrophobic core and a shell having a hydrophilic exterior surface;
- wherein PLGA-g-PEI forms the micelle and has a molecular weight in the range of about 50 kDaltons to about 90 kDaltons, and at least a portion of PLGA of PLGA-g-PEI forms at least a portion of the interior hydrophobic core and at least a portion of PEI of PLGA-g-PEI forms at least a portion of the hydrophilic exterior surface of the shell;
- wherein the PLGA in the PLGA-g-PEI has a molecular weight in a range of 40 kDaltons to about 70 kDaltons and the PLGA is grafted to the PEI of the PgP;
- and
- wherein the micelle has a diameter in a range of about 100 nm to about 300 nm, thereby increasing the therapeutic efficacy of the at least one therapeutic agent in the subject.
A micelle comprising poly(lactide-co-glycolide)-graft-polyethylenimine (PLGA-g-PEI (PgP)) and at least two therapeutic agents,
- wherein the micelle has an interior hydrophobic core and a shell having a hydrophilic exterior surface;
- wherein PLGA-g-PEI forms the micelle, and at least a portion of PLGA of PLGA-g-PEI forms at least a portion of the interior hydrophobic core and at least a portion of PEI of PLGA-g-PEI forms at least a portion of the hydrophilic exterior surface of the shell;
- wherein the at least two therapeutic agents comprise an antiproliferative drug and an antithrombotic drug;
- wherein the micelle has a diameter in a range of about 100 nm to about 300 nm;
- wherein the micelle comprises 3-5 molecules of PLGA grafted to branched chain PEI with the PLGA having a molecular weight of about 50 kDaltons and the branched chain PEI having a molecular weight of about 25 kDaltons;
- and
- wherein the antiproliferative drug is present in the interior hydrophobic core of the micelle and wherein the antithrombotic drug is present on a portion of the hydrophilic exterior surface of the shell.
Dependencies are inferred from the claim text.